Wound botulism is a rare, life-threatening paralytic illness caused by Clostridium botulinum colonization of a wound with in situ production of botulinum neurotoxin, which inhibits acetylcholine release at the presynaptic neuromuscular junction. [1-2] It now accounts for the majority of adult botulism cases in the United States, driven primarily by injection drug use — particularly black tar heroin "skin popping". [3-4]
1. History
- Key HPI questions: Ask about injection drug use (type, route — subcutaneous "skin popping" vs. IV), recent traumatic wounds, crush injuries, or open fractures [3-4]
- Symptom characterization: Symmetric, descending weakness beginning with cranial nerves — blurred vision, diplopia, ptosis, dysphagia, dysarthria, dry mouth [5-6]
- Timing: Incubation typically 4–14 days after wound contamination (longer than foodborne botulism); no preceding GI symptoms (nausea/vomiting are conspicuously absent in wound botulism) [1][7]
- Progression: Cranial nerve palsies → neck weakness → proximal limb weakness → respiratory failure; can progress rapidly [2][8]
- Important negatives: No fever, no altered mental status, no sensory deficits [9]
2. Alarm Features
- Dyspnea, tachypnea, or inability to handle secretions — respiratory failure can occur rapidly with little prior ventilatory deterioration [8]
- Inability to swallow, pooling of secretions
- Rapidly progressive descending paralysis
- Weak cough, declining forced vital capacity
- Loss of gag reflex
- Any bulbar symptoms in a person who injects drugs should trigger immediate consideration of wound botulism [10]
3. Medications
- Antitoxin: Heptavalent botulinum antitoxin (BAT) — the definitive treatment; available only through the state health department and CDC (24/7 emergency release) [11-12]
- Antibiotics for wound botulism: Penicillin G (20 million units/day IV) or metronidazole (500 mg IV q8h) to eradicate the organism from the wound [13-15]
- Avoid aminoglycosides (gentamicin, tobramycin) — these potentiate neuromuscular blockade and can worsen paralysis [14]
- Avoid magnesium sulfate — also potentiates neuromuscular blockade
- Antibiotics are adjunctive; they do not neutralize circulating toxin and should not delay antitoxin administration [2]
4. Diet
- NPO if any dysphagia or aspiration risk
- Enteral nutrition via NG/OG tube once airway is secured
- Parenteral nutrition if prolonged ileus (autonomic dysfunction can cause gastroparesis and constipation)
- No specific dietary triggers; this is a wound-acquired infection
5. Review of Systems
- Neuro: Diplopia, blurred vision, ptosis, facial weakness, dysarthria, dysphagia, limb weakness, difficulty breathing
- Autonomic: Dry mouth, constipation, urinary retention, orthostatic hypotension, fixed/dilated pupils (though normal pupillary response does not exclude botulism — reactive in ~46% of cases) [6]
- Respiratory: Dyspnea, weak cough, inability to clear secretions
- GI: Nausea/vomiting are typically absent in wound botulism (unlike foodborne) [7]
- Skin: Inspect all injection sites, surgical wounds, and traumatic wounds for abscess, crepitus, or devitalized tissue
6. Collateral History and Family History
- Collateral: Confirm drug use history, type of drug (black tar heroin), route of injection (skin popping vs. IV), recent wound or abscess drainage, shared drug supply (cluster cases) [3]
- Social context: Homelessness, lack of access to clean injection supplies, geographic location (US-Mexico border, Western US, and Europe have higher incidence) [6][10]
- Family history: Not relevant; botulism is not hereditary and is not contagious [16]
7. Risk Factors
- Injection drug use — especially subcutaneous ("skin popping") or intramuscular injection of black tar heroin [3][6][10]
- Traumatic wounds (crush injuries, open fractures, gunshot wounds) — rare but reported [4]
- Surgical wounds (very rare)
- Devitalized tissue creating anaerobic conditions favorable for C. botulinum spore germination [17]
- Geographic clustering: Western US (California, Texas border regions), Europe [3][6]
8. Differential Diagnosis
- Guillain-Barré syndrome (GBS): Ascending (not descending) paralysis, elevated CSF protein, areflexia; Miller Fisher variant (descending) can closely mimic botulism [3][9]
- Myasthenia gravis: Fatigable weakness, positive AChR/MuSK antibodies, positive edrophonium test; postsynaptic (vs. presynaptic in botulism) [5][9]
- Lambert-Eaton myasthenic syndrome: Proximal weakness with facilitation, associated with malignancy
- Opioid intoxication/overdose: Miosis, respiratory depression, altered mental status — overlapping features in the IDU population make this a critical diagnostic pitfall [3]
- Stroke (brainstem): Typically asymmetric, abnormal imaging
- Tick paralysis: Ascending paralysis, search scalp for tick [18]
- Organophosphate poisoning: Cholinergic excess (salivation, lacrimation) — opposite of botulism's anticholinergic features
- Diphtheria: Pharyngeal membrane, palatal paralysis
9. Past Medical History
- Prior episodes of botulism (rare but possible with continued drug use)
- History of injection drug use, abscess formation, prior wound infections
- Tetanus vaccination status (co-infection with other Clostridia is possible) [10]
- Chronic wounds, diabetes, immunosuppression (impaired wound healing)
- Prior equine serum exposure (increases risk of hypersensitivity to BAT) [19]
10. Physical Exam
- Vital signs: Typically afebrile; tachycardia may indicate autonomic dysfunction or impending respiratory failure; monitor oxygen saturation closely [9]
- Cranial nerves: Bilateral ptosis, ophthalmoplegia, sluggish or fixed/dilated pupils (but reactive pupils do not exclude diagnosis), facial diplegia ("expressionless face"), weak jaw, dysarthria, absent gag reflex [6][9]
- Motor: Symmetric, descending, flaccid weakness — proximal > distal; neck flexor weakness is common [6]
- Reflexes: Diminished or absent deep tendon reflexes
- Sensory: Normal (a key distinguishing feature from GBS) [8]
- Respiratory: Assess forced vital capacity, negative inspiratory force; watch for paradoxical breathing
- Skin/wound exam: Inspect all injection sites and wounds for abscess, cellulitis, crepitus, or necrotic tissue [10]
11. Lab Studies
- Serum botulinum toxin assay (mouse bioassay) — send through state health department/CDC; results take 1–4 days; do not delay treatment [20]
- Wound culture for anaerobes (specifically C. botulinum) — low yield but supportive if positive [20]
- CBC, BMP, LFTs — typically normal; used to rule out other etiologies
- CSF analysis — normal in botulism (elevated protein suggests GBS) [18]
- Blood cultures — to rule out sepsis
- AChR and MuSK antibodies — to exclude myasthenia gravis [9]
- Urine drug screen — to confirm suspected drug use
12. Imaging
- CT/MRI brain — normal in botulism; used to exclude brainstem stroke or mass lesion [9][13]
- CT of wound/soft tissue — to evaluate for abscess, gas gangrene, or necrotizing soft tissue infection requiring surgical debridement [10]
- Chest X-ray — baseline; monitor for aspiration pneumonia and atelectasis
- Imaging is not diagnostic for botulism — it is used to exclude mimics
13. Special Tests
- Repetitive nerve stimulation (RNS):
- Low-frequency (2–3 Hz): Decremental response (may be absent in mild cases) [21-22]
- High-frequency (50 Hz): Incremental response (facilitation) — most distinctive finding, resembling Lambert-Eaton syndrome but typically less dramatic [18]
- Single supramaximal nerve stimulation: Small-amplitude CMAP in clinically affected muscles — the most consistent electrophysiologic abnormality [22-23]
- Single-fiber EMG (SFEMG): Increased jitter and blocking — most sensitive electrodiagnostic test, especially in mild cases [24]
- Post-exercise facilitation: ≥25% increment in CMAP amplitude after brief maximal voluntary contraction — sensitivity 95%, specificity 100% [25]
- Edrophonium (Tensilon) test: May show partial improvement (unlike the robust response in myasthenia gravis); can help differentiate but is not definitive [18]
14. ECG
- Not a primary diagnostic tool for botulism
- Monitor for autonomic dysfunction: sinus tachycardia, bradycardia, orthostatic changes
- Rare reports of ventricular tachycardia as a complication [12]
- Obtain baseline ECG; continuous telemetry monitoring in ICU
15. Assessment
Wound botulism is a clinical diagnosis based on the triad of: (1) compatible neurologic findings (symmetric descending flaccid paralysis with cranial nerve involvement), (2) a wound or injection site, and (3) absence of features suggesting alternative diagnoses. [2][9]
- Severity stratification: Mild (cranial nerve palsies only) → Moderate (limb weakness) → Severe (respiratory failure requiring intubation); in one case series, 100% of wound botulism patients required mechanical ventilation [6]
- Atypical presentations occur in ~7% of cases — including unilateral cranial nerve findings or ascending paralysis [9]
- Key pearl: The disease is frequently underrecognized because symptoms overlap with opioid intoxication and overdose in the IDU population [3]
16. Treatment Plan
Initial stabilization
- Airway management is the top priority — early intubation for declining respiratory function (FVC <15 mL/kg, NIF weaker than −20 cmH₂O, or clinical deterioration) [1-2]
- Avoid succinylcholine (unpredictable response at dysfunctional NMJ)
Antitoxin
- Heptavalent botulinum antitoxin (BAT) — one vial IV; contact state health department → CDC for emergency release (available 24/7) [11-12]
- Do not delay for lab confirmation — treatment is based on clinical suspicion [2][11]
- Administration within ≤2 days of symptom onset is associated with significantly shorter hospital stay (5 vs. 15.5 days), ICU stay (4 vs. 12 days), and mechanical ventilation duration (6 vs. 14.5 days) [12]
- Anaphylaxis risk ~1–2%; have epinephrine at bedside; skin testing is not recommended to delay treatment [19]
Antibiotics
- Penicillin G 3–4 million units IV q4h or metronidazole 500 mg IV q8h to eradicate wound colonization [13-15]
- Antibiotics do not neutralize circulating toxin
Surgical
Supportive care
- Mechanical ventilation (often prolonged — weeks to months)
- DVT prophylaxis, stress ulcer prophylaxis
- Nutritional support (enteral preferred)
- Physical/occupational therapy during recovery
17. Disposition
- All suspected wound botulism cases require ICU admission — respiratory failure can develop rapidly and unpredictably [2][8]
- Discharge is not appropriate from the ED
- Mandatory public health reporting — botulism is a nationally notifiable disease; contact state/local health department immediately [2][5]
- Surgical consultation for wound debridement [10]
- Neurology consultation for electrodiagnostic studies and ongoing management
- Toxicology/Poison Control consultation may assist with antitoxin coordination [4]
18. Follow Up / Return Precautions
- Recovery is prolonged — weeks to months; driven by regeneration of presynaptic nerve terminals [1]
- Patients discharged from acute care may require long-term acute care (LTAC) or skilled nursing facility placement [6]
- Outpatient neurology follow-up for serial strength assessments
- Substance use disorder treatment referral — critical to prevent recurrence in IDU patients [3][10]
- Tetanus vaccination update if not current [10]
- Return precautions: any new weakness, difficulty breathing, swallowing difficulty, or vision changes warrants immediate re-evaluation
- Expected course: strength improves over weeks to months; fatigue and weakness may persist for up to a year [23]
Images
References
1. Botulism. — Sobel J. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2005.
2. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. — Rao AK, Sobel J, Chatham-Stephens K, Luquez C. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021.
3. Wound Botulism Outbreak Among Persons Who Use Black Tar Heroin - San Diego County, California, 2017-2018. — Peak CM, Rosen H, Kamali A, et al. MMWR. Morbidity and Mortality Weekly Report. 2019.
4. Shot by a Gun … Missed by a Provider. — Garcia E, Zaid AH, Calello DP, et al. The Journal of Emergency Medicine. 2018.
5. Botulism in the United States: A Clinical and Epidemiologic Review. — Shapiro RL, Hatheway C, Swerdlow DL. Annals of Internal Medicine. 1998.
6. Black Tar Heroin Skin Popping as a Cause of Wound Botulism. — Qureshi IA, Qureshi MA, Rauf Afzal M, et al. Neurocritical Care. 2017.
7. Medical Treatment for Botulism. — Chalk CH, Benstead TJ, Pound JD, Keezer MR. The Cochrane Database of Systematic Reviews. 2019.
8. Botulism: A Rare Complication of Injecting Drug Use. — Wenham TN. Emergency Medicine Journal : EMJ. 2008.
9. Clinical Characteristics and Ancillary Test Results Among Patients With Botulism-United States, 2002-2015. — Rao AK, Lin NH, Jackson KA, Mody RK, Griffin PM. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2017.
10. View From the Front Lines: An Emergency Medicine Perspective on Clostridial Infections in Injection Drug Users. — Gonzales y Tucker RD, Frazee B. Anaerobe. 2014.
11. Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin. — Yu PA, Lin NH, Mahon BE, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2017.
12. Safety and Clinical Outcomes of an Equine-Derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States. — Richardson JS, Parrera GS, Astacio H, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2020.
13. Cranial Nerve Palsy Secondary to Botulism After Black Tar Heroin Use. — Suzuki HT, Reddy H. Journal of the American Board of Family Medicine : JABFM. 2021.
14. Susceptibility of Clostridium Botulinum to Thirteen Antimicrobial Agents. — Swenson JM, Thornsberry C, McCroskey LM, Hatheway CL, Dowell VR. Antimicrobial Agents and Chemotherapy. 1980.
15. FDA Drug Label. — Updated date: 2025-02-01. Food and Drug Administration.
16. Clinical Management of Potential Bioterrorism-Related Conditions. — Adalja AA, Toner E, Inglesby TV. The New England Journal of Medicine. 2015.
17. Pathogenicity and Virulence of Clostridium Botulinum. — Rawson AM, Dempster AW, Humphreys CM, Minton NP. Virulence. 2023.
18. Botulinum Toxin as a Biological Weapon: Medical and Public Health Management. — Arnon SS, Schechter R, Inglesby TV, et al. The Journal of the American Medical Association. 2001.
19. Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); And the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review. — Schussler E, Sobel J, Hsu J, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2017.
20. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
21. Botulism: Electrophysiological Studies. — Oh SJ. Annals of Neurology. 1977.
22. Electrophysiologic Methods as an Aid in Diagnosis of Botulism: A Review. — Cherington M. Muscle & Nerve. 1982.
23. Clinical Spectrum of Botulism. — Cherington M. Muscle & Nerve. 1998.
24. Neurophysiological Assessment in the Diagnosis of Botulism: Usefulness of Single-Fiber EMG. — Padua L, Aprile I, Monaco ML, et al. Muscle & Nerve. 1999.
25. Electrodiagnosis of Botulism and Clinico-Electrophysiological Correlation. — Witoonpanich R, Vichayanrat E, Tantisiriwit K, Rattanasiri S, Ingsathit A. Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 2009.